SUTEKAST (sunitinib) inhibits multiple receptor tyrosine kinases involved in tumour growth and angiogenesis.
Recommended for:
Patients with metastatic or inoperable renal cell carcinoma
Inoperable or metastatic gastrointestinal stromal tumours (GIST)
Progressive pancreatic neuroendocrine tumours with limited treatment options
Renal cell carcinoma
Gastrointestinal stromal tumours (GIST)
Pancreatic neuroendocrine tumours
Capsules should be taken orally at the same time each day. Dosage and schedule should be followed exactly as prescribed by your physician, including any on/off treatment cycles.
Contraindications:
Hypersensitivity to sunitinib
Pregnancy and breastfeeding
Severe hepatic impairment
Paediatric use
Side Effects:
Fatigue, weakness
Diarrhoea, nausea
Elevated blood pressure
Thyroid dysfunction
Skin reactions including rash and dryness
Bleeding